Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Microba Life Sciences Limited ( (AU:MAP) ).
Mercer Investments (Australia) Limited, as the responsible entity of the Mercer Australian Small Companies Fund, has ceased to be a substantial holder in Microba Life Sciences Limited as of June 27, 2025. This change follows an increase in the total shares on issue by 67,177,796 shares, impacting the fund’s voting interests in the company.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.26 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences Limited operates in the life sciences industry, focusing on microbiome analysis and related health solutions. The company is engaged in providing insights into gut health through advanced technology and scientific research, catering to both individual consumers and healthcare professionals.
Average Trading Volume: 256,045
Technical Sentiment Signal: Sell
Current Market Cap: A$44.81M
For detailed information about MAP stock, go to TipRanks’ Stock Analysis page.